Navigation Links
Clarient to Commercialize Novel Breast Cancer Profile
Date:1/9/2008

Factors that might cause such a difference include, but are not limited to: Clarient's ability to effectively market the Clarient Insight Dx Breast Cancer Profile and market acceptance of the new test, the ability of Prediction Sciences and Clarient to obtain and maintain necessary regulatory approvals to commercialize the Clarient Insight Dx Breast Cancer Profile (including FDA clearance if determined by the FDA to be necessary or if, as expected, the FDA adopts current proposed guidance to regulate certain in vitro diagnostic devices such as the Clarient Insight Dx Breast Cancer Profile), Clarient's ability to continue to develop and expand its diagnostic services business, Clarient's ability to expand and maintain a successful sales and marketing organization, Clarient's ability to maintain compliance with financial and other covenants under its credit facilities, the continuation of favorable third party payer reimbursement for laboratory tests, unanticipated expenses or liabilities or other adverse events affecting cash flow, uncertainty of success in identifying and developing new diagnostic tests or novel markers, Clarient's ability to compete with other technologies and with emerging competitors in novel cancer diagnostics and dependence on third parties for collaboration in developing new tests, and risks detailed from time to time in the Company's SEC reports, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. Recent experience with respect to laboratory services, revenues and results of operations may not be indicative of future results for the reasons set forth above.

The company does not assume any obligation to update any forward-looking statements or other information contained in this document.

Contact:

Matt Clawson

Allen & Caron, Inc.

(949) 474-4300

matt@allencaron.com


'/>"/>
SOURCE Clarient
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Clarient CEO Ron Andrews to Participate in OneMedPlace Emerging Healthcare Technologies Finance Forum
2. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
3. Neurocrine Biosciences and Dainippon Sumitomo Pharma (DSP) Announce Agreement to Develop and Commercialize Indiplon in Japan
4. Affymax(R) and Takeda Recognized for Innovative Global Agreement to Develop and Commercialize Hematide(TM) for Anemia
5. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
6. New Drug Application for Tolvaptan, Otsukas Investigational Novel Oral Treatment for Worsening Heart Failure and Hyponatremia, Accepted by the U.S. Food and Drug Administration
7. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
8. Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
9. Oxford Genome Sciences and Amgen to Jointly Discover Novel Therapeutic Antibodies in Cancer
10. First European Patient Treated in CABERNET Trial With Novel Treatment for Wet AMD
11. DOE JGI plumbs termite guts to yield novel enzymes for better biofuel production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 2014 Carahsoft and CDS Federal Services ... 2014 at 2pm EST (11am PST), “Natural Language Processing: ... on how technology can turn raw, heterogeneous data into ... agencies. The online webinar will last approximately one hour. ...
(Date:1/14/2014)... , Jan. 14, 2014 As pet owners drew up their ... of them wrote: "Take better care of my furry companion." Nowadays ... clothes and top-brand carrying cases to take the little canine or ... also feel compelled to buy some pricey toys at the pet ...
(Date:1/14/2014)... and BETHESDA, Md. , ... joining together with two institutes from the National Institutes ... tools for bringing safer, more effective treatments to patients ... National Center for Advancing Translational Sciences (NCATS) and the ...
(Date:1/14/2014)...  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company ... addressing major unmet medical needs using RNA-targeted technologies, ... Allowance from the United States Patent and Trademark ... for the treatment of fibrosis. The patent covers ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... Oct. 10 Twenty of Britain,s most,innovative technology ... at the fifth annual SETsquared Partnership Showcase 2008. ... George Street, London, from 8am on,Thursday, October 16th, ... information technology, engineering and biotechnology., Six companies ...
... 10 Takeda Pharmaceutical Company,Limited ("Takeda") today announced ... wholly owned United States (U.S.) subsidiary,received notification that ... be able to complete its review of the ... User Fee Act (PDUFA) date of October 27,2008., ...
... 9 Pairing traditional quality,tools with innovations ... organizations reduce waste, meet customer expectations and ... Process Improvement Leaders,Produce Profits in Recessions, the ... Practices, LLC,s GLOBAL BENCHMARKING COUNCIL,executives from leading ...
Cached Biology Technology:Creators of Britain's Innovation Economy to Showcase the Technologies of the Future at the Fifth SETsquared Partnership Showcase 2008 2Creators of Britain's Innovation Economy to Showcase the Technologies of the Future at the Fifth SETsquared Partnership Showcase 2008 3FDA Continues Review of Takeda's New Drug Application for Alogliptin (SYR-322), a DPP-4 Agent for Type 2 Diabetes 2Six Sigma and Social Media: Tools for Reducing Costs, Improving Processes 2
(Date:4/18/2014)... world population predicted to reach 9 billion by ... that considers human-altered landscapes such as farmland, according ... habitat that supports it might be an increasingly ... three-quarters of the land surface is directly affected ... human-caused impacts such as climate change. But what ...
(Date:4/18/2014)... R.I. [Brown University] Asteroid and comet impacts can ... on regional or even global scales. But new research ... the signatures of ancient life at the time of ... geologist Pete Schultz has found fragments of leaves and ... several ancient impacts in Argentina. The material could provide ...
(Date:4/17/2014)... infection , Respiratory syncytial virus (RSV) is ... generating life-threating illness in very young and elderly ... RSV enters host cells through the fusion protein ... Small interfering peptides that prevent bundle formation limit ... highly susceptible to degradation. In this issue of ...
Breaking Biology News(10 mins):Stanford researchers rethink 'natural' habitat for wildlife 2Stanford researchers rethink 'natural' habitat for wildlife 3Stanford researchers rethink 'natural' habitat for wildlife 4Impact glass stores biodata for millions of years 2Impact glass stores biodata for millions of years 3JCI online ahead of print table of contents for April 17, 2014 2JCI online ahead of print table of contents for April 17, 2014 3JCI online ahead of print table of contents for April 17, 2014 4JCI online ahead of print table of contents for April 17, 2014 5JCI online ahead of print table of contents for April 17, 2014 6
... have discovered that the shape of a protein ... invade the human bloodstream. This,finding, published Dec. 16 ... a vaccine that is significantly more effective at,protecting ... the shape of a large, paddle-like molecule that,Streptococcus ...
... Dartmouth Medical School geneticists have found links in the ... avenues for studying and targeting a process vital to ... The work, reported in the February 17 issue of ... plant, in prompting worm cells to self destruct. These ...
... Two compounds that zero in on cancer cells spreading ... someday give doctors a whole new weapon in the ... College of Cornell University researchers. , The compounds, called ... metastatic breast cancer cells in mice, and are the ...
Cached Biology News:New comparative toxicogenomics database 2New comparative toxicogenomics database 3Critical role in programmed cell death identified 2Critical role in programmed cell death identified 3First-ever Compounds To Target Only Metastatic Cells Are Highly Effective Against Breast, Prostate, And Colon Cancers 2First-ever Compounds To Target Only Metastatic Cells Are Highly Effective Against Breast, Prostate, And Colon Cancers 3